15 May 2019 | News
Treatment of hemorrhoids and anal itching uses slow-release mechanism, offers longer relief to patients with a single treatment per day
image credit- shuttershock.com
Peritech Pharma, a specialty anal-rectal pharmaceutical company based in Israel, has announced it has been granted patents covering China and Russia for its drug delivery platform used for two of its over-the-counter products, PP-110 for hemorrhoids and PP-120 for anal itching.
These new patents contribute to Peritech Pharma's strong IP in the US, and supports its growing international presence to expand beyond its commercial agreements in Brazil and 23 other countries in Central and South America.
These new patents, which also apply to topical skin treatment technology under a license to Topitech Pharma, protect the mechanism that provides patients longer relief from symptoms with fewer applications needed per day.
Peritech's drug delivery platform can be applied quickly and efficiently in the development of new formulations. In a recent randomized, open-label study, patients receiving PP-110 once a day reported considerably better results in terms of reduced pain, bleeding and itching compared to patients treated four times a day with Preparation-H. The results found that PP-110 provided long lasting relief with only a single daily application compared to other products with the same active ingredients.